Stay updated on Pembrolizumab in Relapsed Mediastinal Lymphoma Clinical Trial

Sign up to get notified when there's something new on the Pembrolizumab in Relapsed Mediastinal Lymphoma Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Pembrolizumab in Relapsed Mediastinal Lymphoma Clinical Trial page

  1. Check
    7 days ago
    No Change Detected
  2. Check
    14 days ago
    Change Detected
    Summary
    A site-wide NIH announcement about the transition from “Artificial Intelligence” to “Super Intelligence” terminology was removed. The page continues to display a 403 error.
    Difference
    1%
    Check dated 2026-11-08T04:42:30.000Z thumbnail image
  3. Check
    21 days ago
    Change Detected
    Summary
    The page continues to show a 403 Forbidden error instead of the study record. The footer revision label changed from v3.7.2 to v3.8.0.
    Difference
    0.2%
    Check dated 2026-11-01T02:12:18.000Z thumbnail image
  4. Check
    28 days ago
    Change Detected
    Summary
    A site-wide banner announces that NIH websites are transitioning terminology from “Artificial Intelligence” to “Super Intelligence” and links to updates and FAQs.
    Difference
    1%
    Check dated 2026-10-25T02:09:30.000Z thumbnail image
  5. Check
    35 days ago
    Change Detected
    Summary
    The footer revision indicator changed from v3.7.1 to v3.7.2 while the page continued to display a 403 error.
    Difference
    0.2%
    Check dated 2026-10-18T01:56:48.000Z thumbnail image
  6. Check
    42 days ago
    Change Detected
    Summary
    The ClinicalTrials.gov error page’s footer revision changed from v3.7.0 to v3.7.1, while the page continues to show a 403 Forbidden message.
    Difference
    0.2%
    Check dated 2026-10-11T02:45:32.000Z thumbnail image
  7. Check
    63 days ago
    Change Detected
    Summary
    A 403 Forbidden error page is now displayed, replacing the study record with an error screen. This makes the trial information at this URL unavailable and leaves only general navigation and footer visible.
    Difference
    19%
    Check dated 2026-09-20T01:20:39.000Z thumbnail image

Stay in the know with updates to Pembrolizumab in Relapsed Mediastinal Lymphoma Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Pembrolizumab in Relapsed Mediastinal Lymphoma Clinical Trial page.